文献速递生殖医学

灵活孕激素促排卵方案与GnRH拮抗剂方案在预测低反应患者全胚冷冻周期中的随机非劣效性试验

Flexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial.
PubMed 文献 · Hum Reprod · 2025-01-01

这项非劣效性开放标签随机对照试验在预测卵巢低反应的不孕女性中比较灵活孕激素促排卵方案(fPPOS)与GnRH拮抗剂方案,全胚冷冻后行冻融胚胎移植。按方案分析显示,fPPOS组12个月内每名女性活产率为44.4%(96/216),拮抗剂组为48.9%(114/233),风险比0.91(95%CI 0.74–1.11),风险差-4.5%(95%CI -13.7–4.7),未达到-12.5%的非劣效界值。

要点

  • 在预测低反应患者中,fPPOS方案的12个月活产率未达到相对于GnRH拮抗剂方案的非劣效性标准。
  • fPPOS组活产率44.4%(96/216)vs 拮抗剂组48.9%(114/233),风险差-4.5%(95%CI -13.7–4.7)。
  • 两组卵母细胞和胚胎参数无显著差异,fPPOS组9例(4.17%)发生早发LH峰,拮抗剂组5例(2.15%)。

核心结论

  • 在预测低反应且行全胚冷冻的不孕女性中,fPPOS方案12个月活产可能性未达到相对于标准GnRH拮抗剂方案的非劣效性标准。
  • 作者认为,尽管MPA被认为是计划全胚冷冻周期中拮抗剂的患者友好替代方案,但就活产率而言,GnRH拮抗剂方案仍应是预测低反应患者的首选治疗。

研究设计与样本

  • 非劣效性、开放标签随机对照试验,在三级辅助生殖中心进行。
  • 2020年7月至2023年6月共随机分配484名参与者,按1:1分配。
  • 纳入标准:年龄<40岁、窦卵泡计数<10、基础血清FSH<12 mIU/ml的预测卵巢低反应不孕女性。
  • 干预:当主导卵泡达14 mm时,每日给予MPA 10 mg或GnRH拮抗剂0.25 mg,直至扳机日;两组所有可移植胚胎均冷冻保存,后续行冻融胚胎移植。
  • 主要终点:随机化后12个月内每名女性的活产比例,非劣效界值为-12.5%;按方案人群分析。

主要发现

  • 按方案分析共纳入449名女性,fPPOS组216名,GnRH拮抗剂组233名。
  • 每名女性活产率:fPPOS组44.4%(96/216)vs 拮抗剂组48.9%(114/233),风险比0.91(95%CI 0.74–1.11),风险差-4.5%(95%CI -13.7–4.7),未达到-12.5%的非劣效界值。
  • 两组卵母细胞和胚胎参数无显著差异。
  • fPPOS组9名女性(4.17%)发生早发促黄体生成素(LH)峰,拮抗剂组5名(2.15%)。
  • fPPOS组仅1名女性在取卵前排卵。

临床怎么用

  • 作者认为,尽管MPA被认为是计划全胚冷冻周期中拮抗剂的患者友好替代方案,但就活产率而言,GnRH拮抗剂方案仍应是预测低反应患者的首选治疗。

局限性

  • 开放标签试验中药物给药途径不同导致无法设盲,可能影响结局评估。
  • 所有参与者均来自一个国家的一个中心,限制了普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment? SUMMARY ANSWER: In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy. WHAT IS KNOWN ALREADY: The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections. With milder pituitary suppression, the fPPOS protocol may be a less costly option for women expected to have a low or suboptimal response if a fresh embryo transfer is not intended. STUDY DESIGN, SIZE, DURATION: This was a non-inferiority, open-label randomized controlled trial conducted at a tertiary assisted reproduction center. A total of 484 participants were randomized in the study between July 2020 and June 2023 with a 1:1 allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Infertile women with a predicted suboptimal ovarian response (<40 years old, antral follicle count <10, and basal serum FSH < 12 mIU/ml) were randomly assigned to receive either fPPOS treatment or GnRH antagonist treatment. MPA (10 mg) or GnRH antagonist (0.25 mg) was administered daily once the leading follicle reached 14 mm and continued until the day of trigger. All viable embryos were cryopreserved for subsequent frozen-thawed embryo transfer in both groups. The primary endpoint was the proportion of live births per woman within 12 months post-randomization (with a non-inferiority margin of -12.5%). The analysis was assessed in the per-protocol population. MAIN RESULTS AND THE ROLE OF CHANCE: Twenty-two women withdrew at the beginning of the stimulation phase due to COVID-19. Eight women did not proceed with the assigned frozen embryo transfer, and six switched from the fPPOS to the antagonist protocol. Overall, 449 women were included in the per-protocol analysis, with 216 in the fPPOS group and 233 in the GnRH antagonist group. The LBRs per woman were 44.4% (96/216) for participants in the fPPOS group and 48.9% (114/233) for participants in the GnRH antagonist group [risk ratio (RR) 0.91 (95% CI, 0.74, 1.11), risk difference (RD) -4.5% (95% CI, -13.7, 4.7)], which did not meet the non-inferiority criterion (-12.5%). Oocyte and embryonic parameters were not significantly different between the two groups. Nine women (4.17%) in the fPPOS group experienced a premature luteinizing hormone surge, compared to five women (2.15%) in the antagonist group. Only one woman in the fPPOS group ovulated before oocyte retrieval. LIMITATIONS, REASONS FOR CAUTION: The distinct routes of administration for the medications precluded blinding in this open-label trial, potentially influencing outcome assessments. All participants were recruited in a single center from one country, limiting the generalizability. WIDER IMPLICATIONS OF THE FINDINGS: While MPA is considered a patient-friendly alternative to antagonists for women undergoing scheduled freeze-all cycles, the GnRH antagonist protocol should still be the preferred treatment for anticipated suboptimal responders in terms of LBR. STUDY FUNDING/COMPETING INTEREST(S): This trial was funded by Science and Technology Department of Shaanxi Province, China (2021SF-210). Innovation Team of Shaanxi Provincial Health and Reproductive Medicine Research (2023TD-04); Key Industrial Chain Projects in Shaanxi Province: Research on Assisted Reproductive Technologies and Precision Prevention System for Genetic Diseases Preconception (2023-ZDLSF-48). Science and Technology Department of Shaanxi Province, China (2022SF-564). B.W.M. reports consultancy, travel support and research funding from Merck KGaA and consultancy for Organon and Norgine; owning stock in ObsEva; and holding an NHMRC Investigator Grant (GNT1176437). Other authors declare no conflicts of interest. All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: Registered at Chinese clinical trial registry (www.chictr.org.cn). Registry Identifier: ChiCTR2000030356. TRIAL REGISTRATION DATE: 29 February 2020. DATE OF FIRST PATIENT’S ENROLMENT: 11 March 2020.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cai H, Shi Z, Liu D, et al. Flexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial. Hum Reprod. 2025. PMID: 39729571. doi:10.1093/humrep/deae286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。